{
  "id": 11402408,
  "title": "Pfizer Is Down 34% Over the Last 5 Years. Here's Why Its 6% Dividend Yield Might Finally Be Worth the Risk.",
  "url": "https://urgent.news/2026/10/02/pfizer-is-down-34-over-the-last-5-years-heres-why-its-6-dividend",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-02T08:23:00.000Z",
  "source": {
    "name": "Nasdaq Markets",
    "slug": "nasdaq-markets",
    "url": "https://www.nasdaq.com/articles/pfizer-down-34-over-last-5-years-heres-why-its-6-dividend-yield-might-finally-be-worth"
  },
  "original_language": "en",
  "account": null,
  "summary": "Key PointsPfizer has faced the challenges of declining coronavirus portfolio revenue and patent expirations in recent years.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Motley Fool",
        "title": "Pfizer Is Down 34% Over the Last 5 Years. Here's Why Its 6% Dividend Yield Might Finally Be Worth the Risk.",
        "url": "https://urgent.news/2026/10/02/pfizer-is-down-34-over-the-last-5-years-heres-why-its-6-dividend-11408612",
        "published": "2026-10-02T08:03:00.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}